Article
Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.
Cancer research - 15 Sept 2025
Nie Hao, Liao Liping, Zielinski Rafal J, Gomez Javier A, Basi Akshay V, Seeley Erin H, Tan Lin, Bilecz Agnes Julia, Zhou Wei, Liu Heng, Wang Chen, Wu Shuai, Qi Yuan, Miyamoto Taito, Severi Federica, Goldman Aaron R, Gu Shengqing, Sood Anil K, Jazaeri Amir A, Drapkin Ronny, Claiborne Daniel T, Zhang Nan, Lorenzi Philip L, Burks Jared K, Lengyel Ernst, Gottlieb Eyal, Zhang Rugang
Abstract excerpt
Subunits of the SWI/SNF chromatin remodeling complex are altered in ∼20% of human cancers. Exemplifying the alterations is the ARID1A mutation that occurs in ∼50% of ovarian clear-cell carcinoma (OCCC), a disease with limited therapeutic options. In this study, we showed that ARID1A mutations create a dependence on alanine by regulating alanine transporters to increase intracellular alanine levels. ARID1A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.